Search - tctmd.com

Displaying 1 - 20 of 178

Sort: Relevancy | Date

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Conference News EACTS 2021

Left Main Guideline Review Looms as EACTS Surgeons Urge CABG First

Michael O'Riordan

October 19, 2021

News

Drug-Coated Balloons for CAD: Some International Consensus

L.A. McKeown

May 27, 2020

News Conference News CRT 2020

Meta-analysis Upholds Complete PCI in STEMI, as Thoughts Turn to Timing, Costs

Michael O'Riordan

February 24, 2020

News Daily News

Veterans Study Shows Areas of Need for CLI Care

L.A. McKeown

February 17, 2020

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

L.A. McKeown

February 11, 2020

News Daily News

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Michael O'Riordan

December 10, 2019

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Conference News TCT 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

Todd Neale

September 28, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Conference News EuroPCR 2019

Mortality Appears to Rise When SYNTAX II Score’s Advice for CABG Is Ignored: EXCEL Analysis

L.A. McKeown

June 07, 2019

News Opinion Fellow Talk

Public Reporting and the Budding Interventional Cardiologist

Yashasvi Chugh, MD

March 28, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

L.A. McKeown

February 26, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

Advertisement

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Left Main Guideline Review Looms as EACTS Surgeons Urge CABG First

Drug-Coated Balloons for CAD: Some International Consensus

Meta-analysis Upholds Complete PCI in STEMI, as Thoughts Turn to Timing, Costs

Veterans Study Shows Areas of Need for CLI Care

Outcome Differences Between Men and Women With PAD: EUCLID Insights

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Mortality Appears to Rise When SYNTAX II Score’s Advice for CABG Is Ignored: EXCEL Analysis

Public Reporting and the Budding Interventional Cardiologist

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content